CliffBio
biologic

Avastin

bevacizumab

Loss of exclusivityFebruary 2016projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameAvastin
Active ingredientbevacizumab
Strength100MG/4ML (25MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2004
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Avastin patent cliff — loss of exclusivity February 2016 | CliffBio